Chin-Yuan Tzen1, Bey-Liing Mau. 1. Department of Pathology, Mackay Memorial Hospital, 45, Minsheng Road, Tamshui, Taipei, Taiwan, China. jeffrey@ms2.mmh.org.tw
Abstract
AIM: To identify the gastrointestinal stromal tumors (GISTs) that are negative for CD117 expression by immunohistochemistry and to characterize their malignant potential. METHODS: A total of 108 primary mesenchymal tumors of the gastrointestinal tract were screened to select CD117-negative tumors, from which KIT (exons 9, 11, 13, and 17) and PDGFRA (exons 10, 12, 14, and 18) were sequenced to identify GISTs. Tumor recurrence and distant metastasis were used as the criteria of malignancy. RESULTS: The result showed that approximately 25% (29/108) of the gastrointestinal mesenchymal tumors were negative for CD117 and approximately 6% (7/108) of the tumors were CD117-negative GISTs. All these CD117-negative tumors had a mutated KIT and a wild-type PDGFRA. All CD117-negative GISTs with mutations at codons 557/558 of KIT had mitotic counts >10/50 high power field, and 75% (3/4) of them showed multiple recurrence or distant metastasis. CONCLUSION: CD117-negative KIT mutated GISTs account for approximately 6% of the gastrointestinal mesenchymal tumors. Tumor recurrence or distant metastasis correlates to both the KIT mutations at codons 557/558 and the mitotic counts, but not to the tumor size.
AIM: To identify the gastrointestinal stromal tumors (GISTs) that are negative for CD117 expression by immunohistochemistry and to characterize their malignant potential. METHODS: A total of 108 primary mesenchymal tumors of the gastrointestinal tract were screened to select CD117-negative tumors, from which KIT (exons 9, 11, 13, and 17) and PDGFRA (exons 10, 12, 14, and 18) were sequenced to identify GISTs. Tumor recurrence and distant metastasis were used as the criteria of malignancy. RESULTS: The result showed that approximately 25% (29/108) of the gastrointestinal mesenchymal tumors were negative for CD117 and approximately 6% (7/108) of the tumors were CD117-negative GISTs. All these CD117-negative tumors had a mutated KIT and a wild-type PDGFRA. All CD117-negative GISTs with mutations at codons 557/558 of KIT had mitotic counts >10/50 high power field, and 75% (3/4) of them showed multiple recurrence or distant metastasis. CONCLUSION:CD117-negative KIT mutated GISTs account for approximately 6% of the gastrointestinal mesenchymal tumors. Tumor recurrence or distant metastasis correlates to both the KIT mutations at codons 557/558 and the mitotic counts, but not to the tumor size.
Authors: J Lasota; A Wozniak; M Sarlomo-Rikala; J Rys; R Kordek; A Nassar; L H Sobin; M Miettinen Journal: Am J Pathol Date: 2000-10 Impact factor: 4.307
Authors: Markku Miettinen; Janusz Kopczynski; Hala R Makhlouf; Maarit Sarlomo-Rikala; Hajnalka Gyorffy; Allen Burke; Leslie H Sobin; Jerzy Lasota Journal: Am J Surg Pathol Date: 2003-05 Impact factor: 6.394
Authors: Samuel Singer; Brian P Rubin; Marcia L Lux; Chang-Jie Chen; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544
Authors: Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss Journal: Hum Pathol Date: 2002-05 Impact factor: 3.466
Authors: Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher Journal: Science Date: 2003-01-09 Impact factor: 47.728
Authors: Patricia Rusa Pereira; Alexandre Nakao Odashiro; Jean Claude Marshall; Zelia Maria Correa; Rubens Belfort; Miguel N Burnier Journal: J Carcinog Date: 2005-10-19